IDH1 and central nervous system cancer: Meanwhile, it was found that MGMT promoter methylation is a predictive marker for benefit from alkylating agents only in high-grade glioma patients with IDH1 wildtype, but 1p/19q loss in high-grade glioma patients with IDH1 mutant [7].